LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
Farzaneh Atashrazm,1 Nicolas Dzamko2 1Neuroscience Research Australia, Randwick; 2School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia Abstract: Major advances in understanding how genetics underlies Parkinson’s disease (PD) have provid...
Main Authors: | Atashrazm F, Dzamko N |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-10-01
|
Series: | Clinical Pharmacology: Advances and Applications |
Subjects: | |
Online Access: | https://www.dovepress.com/lrrk2-inhibitors-and-their-potential-in-the-treatment-of-parkinsonrsqu-peer-reviewed-article-CPAA |
Similar Items
-
LRRK2-Related Parkinson’s Disease Due to Altered Endolysosomal Biology With Variable Lewy Body Pathology: A Hypothesis
by: Pilar Rivero-Ríos, et al.
Published: (2020-06-01) -
Autophagy and LRRK2 in the Aging Brain
by: Federica Albanese, et al.
Published: (2019-12-01) -
LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same
by: Daniel C. Berwick, et al.
Published: (2019-12-01) -
Novel ethyl methanesulfonate (EMS)-induced null alleles of the Drosophila homolog of LRRK2 reveal a crucial role in endolysosomal functions and autophagy in vivo
by: Mark W. Dodson, et al.
Published: (2014-12-01) -
The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System
by: Tomoki Kuwahara, et al.
Published: (2020-03-01)